一、药品的基本情况 产品名称：聚乙二醇重组人生长激素注射液 证券代码：000661 证券简称：长春高新 公告编号：2024-110 长春高新技术产业（集团）股份有限公司 关于子公司聚乙二醇重组人生长激素注射液 新适应症上市申请获得批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）子公 司——长春金赛药业有限责任公司（以下简称"金赛药业"）聚乙二醇重组人生 长激素注射液（以下简称"长效生长激素"）新适应症上市申请获得国家药品监 督管理局（以下简称"国家药监局"）批准。现将相关情况公告如下： 商品名：金赛增 特发性身材矮小是一组尚未明确病因，高度异质的矮小疾病的统称，指身 高低于同年龄、性别和种族的平均身高 2 个标准差（standard deviation, SD） 或低于第 3 百分位数（P3，-1.88 SD），且出生身长、体重及身材比例均正 常，未发现全身性、内分泌、营养、染色体异常或基因变异证据的矮小儿童。 2003 年美国食品药品监督管理局（FDA）首次批准重组人生长激素用于特 发 ...

代表其个人观点会议内容并不构成对任何人的投资建议卫星国机证讯事先说明许可任何机构或个人严禁以任何形式将会议内容和相关信息对外公布转发转载传播复制编辑修改解读等好的最近这个投资者大家家不好啊 我是国进证券的医药手机分析师袁伟那么今天我和友商一起我们非常荣幸的邀请到堂堂高薪的总理李总来给我们做一个三级报的一个业绩的交流和解读那么和我一起参会的有我的同事马其中还有来自德邦证券明升证券中泰证券中金公司新业证券新浪红原证券国盛证券 华西证券 华湖证券 广发证券 华安证券和长江证券的同仁们那么我们非常感谢李总愿意抽出时间来和我们做一个交流那么应该说其实整个三级度整个医药板块从目前已经披露的三级报来看整体还是面临一些这个这个金融上的这种紧急度升的压力或者说挑战但我们其实也看到了一到三级度其实 现在仍然整体保持的是一个收入端保持了一个正增长那么同时呢这个公司整体的费用会相对多一些那可否请李总来给我们做一个这个三级化情况的介绍和简要的解读 谢谢感谢院长 非常感谢首先感谢各位这个南方分析室在这个公司现在这么一个经营状态下它依然对公司保持着比较好的一个坚定的一个支持 然后呢也非常非常感谢就是大家的百忙之间在这个周末这个时间节点然后 ...

关于完成工商变更登记并换发营业执照的公告 证券代码：000661 证券简称：长春高新 公告编号：2024-109 长春高新技术产业（集团）股份有限公司 长春高新技术产业（集团）股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 董事会 2024 年 10 月 29 日 长春高新技术产业（集团）股份有限公司（以下简称"公司"）于 2024 年 7 月 19 日召开的第十一届董事会第二次会议、第十一届监事会第二次会议及 2024 年 8 月 5 日召开的 2024 年第三次临时股东大会，先后审议通过了《关于终止实施 2022 年限制 性股票与股票期权激励计划暨回购注销限制性股票及注销股票期权的议案》《关于变 更注册资本并修改〈公司章程〉的议案》相关事项，同意回购注销剩余全部限制性股 票 2,132,101 股，并将注册资本由人民币肆亿零肆佰肆拾贰万叁仟零玖拾元变更为肆 亿零贰佰贰拾玖万零玖佰捌拾玖元。具体内容详见公司在巨潮资讯网上披露的《第十 一届董事会第二次会议决议公告》《第十一届监事会第二次会议决议公告》《2024 年第 三次临时股东大会决议公告》等 ...

证券代码：000661 证券简称：长春高新 长春高新技术产业（集团）股份有限公司 投资者关系活动记录表 编号：2024-007 | --- | --- | --- | |----------------|---------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The report maintains a "Recommended" rating for the company [1] Core Views - The company, Changchun High New Technology Industry Group Co., Ltd., reported a revenue of 10.388 billion yuan for Q3 2024, a year-on-year decrease of 3%, and a net profit attributable to shareholders of 2.789 billion yuan, down 23% year-on-year [1] - The subsidiary, Jinsai Pharmaceutical, achieved revenue of 8.163 billion yuan, a slight increase of 0.55% year-on-year, while its net profit attributable to shareholders decreased by 19% to 2.839 billion yuan, primarily due to increased R&D expenses [1] - Jinsai Pharmaceutical is in a critical transformation phase, with multiple products expected to be launched next year, including those in the women's and children's health sectors [1] Financial Performance Summary - For 2024, the company is projected to achieve a net profit of 4.099 billion yuan, with corresponding P/E ratios of 10, 9, and 8 for the years 2024, 2025, and 2026 respectively [4] - The revenue forecast for 2024 is 15.059 billion yuan, reflecting a growth rate of 3.39% compared to 2023 [4] - The gross profit margin is expected to remain stable around 84.90% in 2024 [4] Product Development and Market Expansion - Several innovative products are expected to be launched soon, which may provide a second growth curve for the company [1] - The company is expanding its product line to include treatments for acute gouty arthritis and central precocious puberty, among others [1] - The overseas business is showing promising trends, particularly in the growth hormone segment [1]

证券代码：000661 证券简称：长春高新 公告编号：2024-107 2、本次对外投资不构成《上市公司重大资产重组管理办法》规定的重大资产 重组。 3、特别风险提示：本次对外投资事项目前处于筹备阶段，合作各方尚未正式 签署合伙协议、尚需完成基金注册登记备案。如遇不可预计或不可抗力等其他因 素的影响，可能存在设立过程中因审批未获通过、登记备案未能完成等风险。投 资基金在运营过程中可能受到宏观经济、行业周期、政策变化、投资标的、经营 管理、交易方案等多种因素影响，存在投资失败或收益不及预期的风险；投资基 金具体实施情况和进度存在不确定性风险。敬请广大投资者谨慎决策，注意投资 风险。 一、对外投资概述 为进一步提升产业投资能力，提高资金使用效率，长春高新技术产业（集团） 股份有限公司（以下简称"公司""长春高新"）于 2024 年 10 月 24 日召开第十 一届董事会第五次会议审议通过了《关于公司拟与专业投资机构共同投资设立合 伙企业的议案》，同意公司与中信建投资本管理有限公司（以下简称"中信建投 资本"）、长春长发私募基金管理有限公司（以下简称"长发私募"）及其他有 限合伙人共同出资成立长春星河润信致诚生物医 ...

长春高新技术产业（集团）股份有限公司 关于为子公司申请银行授信提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保事项概述 长春高新技术产业（集团）股份有限公司（以下简称"公司"）持有控股子 公司——长春金赛药业有限责任公司（以下简称"金赛药业"）99.5%的股权。 金赛药业旗下全资子公司上海赛增医疗科技有限公司（以下简称"上海赛增"） 目前承担建设金赛药业位于上海的科创总部及研发中心项目。 为了满足该项目建设工程资金需要，金赛药业及其子公司上海赛增共同向国 家开发银行吉林省分行及上海市分行申请包含前期贷款及长期贷款合计 15 亿元 的借款授信额度，专项用于金赛药业上海科创总部及研发中心项目建设，具体借 款金额将按照金赛药业该项目实际建设进度需要分期发放。公司董事会同意为其 本次借款授信提供连带责任保证担保，保证期限为 15 年，借款利率以后续签署 的借款合同为准。同时，上海赛增以本项目建成后形成固定资产（主要为科创总 部及研发中心大楼，不含研发设备）以及土地使用权，为该项目贷款提供抵押担 保。董事会授权公司及金赛药业管理层具体实施后续事项 ...

证券代码：000661 证券简称：长春高新 公告编号：2024-105 长春高新技术产业（集团）股份有限公司 第十一届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 1、《2024 年三季度报告》 表决结果：9 票同意，0 票反对，0 票弃权。 具体内容详见公司于同日在巨潮资讯网（www.cninfo.com.cn）披露的《2024 年三季度报告》。 一、董事会会议召开情况 1、经长春高新技术产业（集团）股份有限公司（以下简称"公司"）半数 以上董事同意，第十一届董事会第五次会议于 2024 年 10 月 21 日以电话及微信 方式发出会议通知。 2、本次董事会于 2024 年 10 月 24 日上午 9 时以现场及通讯会议方式召开。 3、本次会议应参与表决董事 9 名，实际参与表决董事 9 名。 4、会议由董事长姜云涛先生主持，公司监事、高级管理人员列席了本次会 议。 5、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 二、董事会会议审议情况 经与会董事认真讨论，审议并通过了如下议案： 2、深交所 ...

Revenue and Profit Performance - Revenue for Q3 2024 was 3.75 billion yuan, a decrease of 16.94% year-over-year[3] - Net profit attributable to shareholders for Q3 2024 was 1.07 billion yuan, down 26.37% year-over-year[3] - Total revenue for the first three quarters of 2024 was 10.39 billion yuan, a decrease of 2.75% year-over-year[6] - Net profit attributable to shareholders for the first three quarters of 2024 was 2.79 billion yuan, down 22.8% year-over-year[6] - Total operating income for the current period is RMB 10,387,939,088.74, compared to RMB 10,681,707,158.20 in the previous period[15] - Net profit for the current period is RMB 2,922,032,804.68, down from RMB 3,783,683,465.89 in the previous period[16] - Net profit attributable to the parent company's shareholders is RMB 2,788,885,490.15, compared to RMB 3,612,424,090.35 in the previous period[16] - Basic earnings per share (EPS) for the current period is RMB 6.93, down from RMB 8.98 in the previous period[17] - Diluted earnings per share (EPS) for the current period is RMB 6.83, down from RMB 8.86 in the previous period[17] - Total comprehensive income for the current period is RMB 2,905,178,346.73, compared to RMB 3,776,440,386.98 in the previous period[17] Subsidiary Performance - Subsidiary Jinsai Pharmaceutical achieved revenue of 8.16 billion yuan, a slight increase of 0.55% year-over-year[6] - Subsidiary Baike Biotech's revenue decreased by 17.47% year-over-year to 1.03 billion yuan[6] - Subsidiary Huakang Pharmaceutical's revenue increased by 11.01% year-over-year to 572 million yuan[6] Expenses and Costs - Prepayments increased by 288 million yuan, up 46.43% compared to the beginning of the year, due to increased material procurement and R&D expenses[6] - Management expenses increased by 272 million yuan, up 48.18% year-over-year, due to organizational adjustments and new subsidiary setups[7] - Operating costs for the current period are RMB 6,868,215,904.85, with a significant decrease in cost of sales to RMB 1,495,915,022.13 from RMB 1,611,988,406.57 in the previous period[15] - Sales expenses increased to RMB 3,144,355,406.06 from RMB 2,815,072,002.15 in the previous period[16] - R&D expenses rose to RMB 1,409,774,640.06 from RMB 1,166,638,725.36 in the previous period[16] - Cash paid for employee compensation and benefits increased to RMB 2,494,641,902.15 from RMB 2,009,788,554.87 in the previous year[18] - Cash paid for taxes and fees rose to RMB 1,205,565,821.66 from RMB 1,032,063,428.90 in the same period last year[18] Assets and Liabilities - Total assets as of September 30, 2024, amounted to RMB 31,072,779,833.46, compared to RMB 30,743,650,924.81 at the beginning of the year[12] - Current assets totaled RMB 16,837,490,904.40, a decrease from RMB 18,164,855,480.07 at the beginning of the year[11] - Non-current assets increased to RMB 14,235,288,929.06 from RMB 12,578,795,444.74 at the beginning of the year[12] - Monetary funds decreased to RMB 6,455,232,638.88 from RMB 7,583,812,274.09 at the beginning of the year[10] - Accounts receivable decreased to RMB 3,083,204,426.91 from RMB 3,214,279,382.15 at the beginning of the year[11] - Inventory decreased to RMB 4,564,700,024.88 from RMB 4,956,286,771.35 at the beginning of the year[11] - Fixed assets increased to RMB 4,342,869,424.37 from RMB 3,801,995,117.33 at the beginning of the year[12] - Construction in progress increased to RMB 3,691,287,222.14 from RMB 2,850,236,949.19 at the beginning of the year[12] - Development expenditure increased to RMB 1,462,606,342.70 from RMB 1,157,051,563.35 at the beginning of the year[12] - Total liabilities as of September 30, 2024, included short-term borrowings of RMB 83,809,437.97, down from RMB 144,472,018.39 at the beginning of the year[12] - Long-term loans increased by 677 million yuan, up 383.43% compared to the beginning of the year, due to bank borrowings by subsidiaries[7] Cash Flow - Operating cash flow for the period was RMB 3,095,834,053.88, a decrease from RMB 3,623,708,358.85 in the same period last year[18] - Net cash flow from investing activities was negative RMB 1,790,848,843.66, compared to negative RMB 1,518,183,118.91 in the previous year[19] - Net cash flow from financing activities was negative RMB 2,432,952,574.81, a significant increase in outflow compared to negative RMB 442,453,022.15 in the prior year[19] - Total cash and cash equivalents at the end of the period were RMB 6,410,600,754.19, down from RMB 7,122,084,845.71 at the end of the previous year[19] - Cash received from sales of goods and services is RMB 10,917,920,125.25, up from RMB 10,211,176,454.66 in the previous period[17] - Cash received from other operating activities was RMB 304,963,809.40, a decrease from RMB 344,084,163.57 in the same period last year[18] - Cash outflow for the purchase of fixed assets, intangible assets, and other long-term assets increased to RMB 1,589,851,431.71 from RMB 1,331,047,190.50 in the previous year[19] - Cash received from borrowings increased significantly to RMB 1,018,528,432.85 from RMB 384,412,607.55 in the same period last year[19] Audit and Reporting - The company's third quarter report was not audited[20]

证券代码：000661 证券简称：长春高新 公告编号：2024-104 长春高新技术产业（集团）股份有限公司 关于子公司注射用人生长激素增加新规格补充申请获得国家药监局 批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）子公 司——长春金赛药业有限责任公司（以下简称"金赛药业"）已上市产品注射用 人生长激素增加 6.0IU/2.0mg/1.0ml/瓶规格（以下简称 6IU 规格）申请获得国家 药品监督管理局批准。现将相关情况公告如下： 一、药品的基本情况 产品名称：注射用人生长激素（商品名，赛增） 申请事项：新增规格补充申请 受理号：CYSB2300135 申请人：长春金赛药业有限责任公司 适应症：同原获批规格适应症 审批结论：符合药品注册的有关要求，批准本品如下事项：本产品在原规格 基础上，增加 6.0IU/2.0mg/1.0ml/瓶的规格。 规格：6.0IU/2.0mg/1.0ml/瓶 二、药品的其它情况 赛增®粉针目前已经获批因内源性生长激素缺乏（GHD）、Noonan 综合征、 S ...